Premium
The Carlyle Group’s deal to take control of SeQuent Scientific Ltd appears to have come at a premium for the private equity firm when compared with the Indian animal healthcare company’s much bigger peers overseas. The PE firm has agreed to acquire up to 74% of SeQuent for Rs 1,580 crore ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
